Report results from two Phase 3 trials of high-dose aflibercept in wet AMD and DME
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Nov 2021
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The high-dose aflibercept formulation is currently also being evaluated in two large Phase 3 trials in wet AMD and diabetic macular edema (DME), which are expected to report results in the second half of 2022.”
What we found
Evidence strength A What the grades mean
The 10-K filed 2023-02-06 states that in September 2022 the company announced primary endpoints were met in two pivotal aflibercept 8 mg trials in DME and wet AMD, within the second half of 2022.
-
A Regeneron Pharmaceuticals 10-K filed 2023-02-06
“In September 2022, the Company announced that the primary endpoints were met in two pivotal trials investigating aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wet AMD.” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-K filed 2023-02-06
“Reported that Phase 3 trials in wet AMD and DME met their primary endpoints” ✓ confirmed on the page
Market reaction: the shares moved -3.9% against the S&P 500 over the three sessions around the disclosure (3 Feb 2023 to 8 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- High-dose aflibercept Phase 3 trial results in wet AMD and DME
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-REGN-006335 · Corrections policy